GeNeuro Targeting Retrovirus Via MAbs in MS, Schizophrenia

Spun out in 2006 from French diagnostics firm BioMérieux SA with the help of Swiss bioincubator Eclosion, GeNeuro SA has slowly but steadily progressed its monoclonal antibody (mAb) technology – initially to prevent the inflammatory and autoimmune cascades induced by the multiple sclerosis-associated retrovirus (MSRV).